false 0001808898 0001808898 2024-12-04 2024-12-04

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 4, 2024

 

 

BENITEC BIOPHARMA INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-39267   84-4620206

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

3940 Trust Way, Hayward, California   94545
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s Telephone Number, Including Area Code: (510) 780-0819

(Former Name or Former Address, if Changed Since Last Report): Not Applicable

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, par value $0.0001   BNTC   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.07

Submission of Matters to a Vote of Security Holders.

On December 4, 2024, Benitec Biopharma Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (the “2024 Annual Meeting”). The 2024 Annual Meeting was held virtually. A total of 17,993,811 shares of the Company’s common stock were present or represented by proxy at the 2024 Annual Meeting, representing 90.81% of the issued and outstanding shares entitled to vote at the meeting. The proposals voted upon and the final results of the vote were as follows:

Proposal 1 – Election of Directors. The results were as follows:

 

Director Nominee

    For      Withhold      Broker Non-Votes  

J. Kevin Buchi

      17,306,616        21,771        665,424  

Peter Francis

      16,452,185        876,202        665,424  

Proposal 2 – Ratification of Appointment of Independent Registered Public Accounting Firm. The results were as follows:

 

For

  

Against

  

Abstain

17,978,704   260   14,847

Proposal 3 – Advisory Vote on Executive Compensation. The results were as follows:

 

For

  

Against

  

Abstain

  

Broker Non-Vote

17,307,680   6,148   14,559   665,424

Proposal 4 – Approval of an Amendment to the Company’s Certificate of Incorporation to Authorize the Issuance of Up to 5,000,000 Shares of Preferred Stock. The results were as follows:

 

For

  

Against

  

Abstain

  

Broker Non-Vote

15,313,718   1,999,102   15,567   665,424

Each of the proposals received the required number of votes to be approved by the Company’s stockholders.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    BENITEC BIOPHARMA INC.
Date: December 6, 2024     By:  

/s/ Jerel A. Banks

    Name:   Jerel A. Banks
    Title:   Chief Executive Officer
v3.24.3
Document and Entity Information
Dec. 04, 2024
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001808898
Document Type 8-K
Document Period End Date Dec. 04, 2024
Entity Registrant Name BENITEC BIOPHARMA INC.
Entity Incorporation State Country Code DE
Entity File Number 001-39267
Entity Tax Identification Number 84-4620206
Entity Address, Address Line One 3940 Trust Way
Entity Address, City or Town Hayward
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94545
City Area Code (510)
Local Phone Number 780-0819
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.0001
Trading Symbol BNTC
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Benitec Biopharma (NASDAQ:BNTC)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024 Haga Click aquí para más Gráficas Benitec Biopharma.
Benitec Biopharma (NASDAQ:BNTC)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024 Haga Click aquí para más Gráficas Benitec Biopharma.